Markets

Here's Why You Should Invest in Stryker (SYK) Stock Now

Stryker CorporationSYK is currently a top performer in the MedTech space. Improved price performance and strong fundamentals instill investors' confidence in the stock. Therefore, its time you advantage from the stock price appreciation.

In the past year, Stryker's shares have rallied 22.3%, significantly outperforming the industry 's growth of 14.6%.

In the last 60 days, the Zacks Consensus Estimate for earnings per share rose 1.8% to $1.73. The company has a Zacks Rank #2 (Buy), which indicates possibility of outperformance in the near term.

Let's find out whether the bullish trend can sustain the stock's impressive performance in the long run.

What Makes It an Attractive Pick?

Focus on Inorganic Growth

Stryker has been leveraging on bolt-on buyouts to drive inorganic growth. Stryker recently acquired Entellus Medical, Inc. for $662 million. Stryker also acquired VEXIM in the recent past which specializes in the development and sale of vertebral compression fracture solutions for €183 million. In 2017, the company closed the buyout of NOVADAQ for a net purchase price of $674 million.

In the last reported quarter, all the buyouts have proven accretive to Stryker.

Mako Propels Growth

Mako is Stryker's robotic-arm assisted surgery platform. The first quarter of 2018 saw another strong show by the Mako Total Knee platform. Per management, the primary growth drivers included continued demand for the Mako TKA knee platform and 3D-printed products in the foot and ankle portfolio. In the reported quarter, the company installed a total of 28 robots globally with 24 in the United States, reflecting an increase of 33.3% year over year.

Guidance Solid

Buoyed by a stellar first quarter, Stryker expects second-quarter earnings per share of $1.70-$1.75. Notably, the Zacks Consensus Estimate for earnings is pegged at $1.73, which is within the given range.

Moreover, organic net sales growth in 2018 is expected within 6.5-7% and adjusted net earnings per diluted share in the range of $7.18-$7.25.

Management is also confident of a 30-50 basis point improvement in operating margin.

Other Key Picks

Some other top-ranked medical stocks are Abiomed, Inc. ABMD , Varian Medical VAR and Intuitive Surgical Inc. ISRG .

Abiomed has an expected long-term earnings growth rate of 27%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Intuitive Surgical has an expected long-term earnings growth rate of 12.1%. The stock sports a Zacks Rank #1.

Varian Medical has a projected long-term earnings growth rate of 8%. The stock carries a Zacks Rank #2.

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report

Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report

ABIOMED, Inc. (ABMD): Free Stock Analysis Report

Stryker Corporation (SYK): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ABMD SYK ISRG

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More